Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study

Phase 4 Completed 20 enrolled Fundación Huésped ViiV Healthcare · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients

Timeline

Start: 2014-10
Primary completion: 2016-03
Completion: 2017-04

Outcome

Met primary endpoint

paper At week 48, 90% (18/20) reached the primary endpoint of a pVL <50 copies/mL. PMID 28537061 ↗

Publications

Cahn P, Rolon MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017 May 9;20(1):21678. doi: 10.7448/IAS.20.01.21678.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dolutegravir	Other / unclassified	50 mg	—
Subject	Lamivudine	Other / unclassified	300 mg	—